Eton Pharmaceuticals, Inc. (ETON) FY2026 Q2 P&L / Income Statement

Eton Pharmaceuticals, Inc. (ETON) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

Total net revenues

37,589,000 US dollars

Product sales and royalties, net

12,176,000 US dollars

Gross profit

25,413,000 US dollars

Total operating expenses

12,619,000 US dollars

Income (loss) from operations

12,794,000 US dollars

Other income (expense), net (calculated)

negative 1,076,000 US dollars

Income (loss) before income tax expense

11,718,000 US dollars

Income tax expense

140,000 US dollars

Net income (loss)

11,578,000 US dollars

Product revenue

37,589,000 US dollars

License revenue

0 US dollars

Product cost of revenue

12,176,000 US dollars

License cost of revenue

0 US dollars

General and administrative

11,626,000 US dollars

Research and development

993,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.